Topical Lung T3 Therapy for COVID-19 ARDS

Recruiting in Palo Alto (17 mi)

Overseen by Timothy P Rich, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: University of Minnesota

Prior Safety Data

Trial Summary

What is the purpose of this trial?

Acute treatment of COVID-ARDS with direct topical lung instilled T3 therapy for patients on mechanical ventilation.

Research Team

Timothy P Rich, MD

Principal Investigator

University of Minnesota

David Ingbar, MD

Principal Investigator

University of Minnesota

Eligibility Criteria

This trial is for patients with severe COVID-19-related lung damage (ARDS) who meet specific criteria, including recent onset of symptoms, certain x-ray findings, and need for mechanical breathing support. They must have a confirmed SARS-CoV-2 infection within the last 14 days. Pregnant individuals cannot participate.

Inclusion Criteria

You have been diagnosed with acute respiratory distress syndrome (ARDS) based on specific criteria, including chest X-ray showing certain patterns, needing mechanical ventilation or oxygen support, and having low oxygen levels in the blood.

You tested positive for COVID-19 within the past two weeks.

Exclusion Criteria

Pregnancy

Treatment Details

Interventions

• Instilled T3 (Thyroid Hormone)
• Placebo Therapy (Other)

Trial Overview The study is testing whether directly applying T3 to the lungs of patients on ventilators can improve outcomes compared to a placebo. Patients are randomly assigned to receive either the actual T3 treatment or a placebo without any active medication.

Participant Groups

Group I: T3 Intervention Experimental Treatment 1 Intervention

Participants in this arm will receive the experimental intervention.

Group II: Placebo Therapy Placebo Group 1 Intervention

Participants in this arm will receive placebo therapy.

Who Is Running the Clinical Trial?

University of Minnesota

Lead Sponsor

Trials

1,459

Recruited

1,623,000+

Shashank Priya

University of Minnesota

Chief Executive Officer since 2023

PhD in Materials Engineering from Penn State

Charles Semba

University of Minnesota

Chief Medical Officer since 2021

MD from the University of Minnesota Medical School